{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:36:51Z","timestamp":1792654611400,"version":"4.5.0"},"reference-count":13,"publisher":"Sociedade Brasileira de Cardiologia","issue":"7","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Bras. Cardiol."],"abstract":"<jats:p>Resumo  Fundamento: Sacubitril\/valsartana reduziu a mortalidade e as hospitaliza\u00e7\u00f5es em pacientes com insufici\u00eancia card\u00edaca com fra\u00e7\u00e3o de eje\u00e7\u00e3o reduzida (ICFEr) em compara\u00e7\u00e3o com enalapril em estudos cl\u00ednicos pivotais. No entanto, os dados de mundo real sob doses otimizadas continuam limitados.  Objetivo: Comparar os desfechos de pacientes com ICFEr tratados com sacubitril\/valsartana versus enalapril ou losartana nas doses m\u00e1ximas recomendadas pelas diretrizes.  M\u00e9todos: Analisamos dados de uma coorte observacional de insufici\u00eancia card\u00edaca (n = 2.314), incluindo pacientes atendidos entre agosto de 2010 e setembro de 2024 em seis hospitais p\u00fablicos de uma grande \u00e1rea metropolitana. A an\u00e1lise prim\u00e1ria incluiu 254 pacientes com ICFEr que receberam as doses m\u00e1ximas recomendadas pelas diretrizes dos medicamentos investigados. Uma an\u00e1lise de sensibilidade incluiu 452 pacientes que receberam quaisquer doses subm\u00e1ximas. O desfecho prim\u00e1rio foi a combina\u00e7\u00e3o de hospitaliza\u00e7\u00e3o ou \u00f3bito. As diferen\u00e7as basais foram ajustadas por meio do pareamento por escore de propens\u00e3o. Foram considerados significativos valores de p &lt; 0,05.  Resultados: Entre 254 pacientes com ICFEr (idade m\u00e9dia de 63,6 \u00b1 12,3 anos, 61,4% do sexo masculino), 115 receberam sacubitril\/valsartana 97\/103 mg duas vezes ao dia, 33 enalapril 20 mg duas vezes ao dia e 106 losartana 100 mg ao dia. Durante um seguimento mediano de 23,9 meses (intervalo interquartil 11,9\u201341,1), ocorreram 70 eventos do desfecho prim\u00e1rio (56 primeiras hospitaliza\u00e7\u00f5es e 32 \u00f3bitos). Em compara\u00e7\u00e3o com doses equivalentes de enalapril ou losartana, sacubitril\/valsartana n\u00e3o foi associado a redu\u00e7\u00f5es significativas na combina\u00e7\u00e3o de hospitaliza\u00e7\u00e3o ou mortalidade (odds ratio 0,650, intervalo de confian\u00e7a de 95% 0,354\u20131,195, p = 0,165), mas foi associado \u00e0 melhora do estado funcional (odds ratio 3,902, intervalo de confian\u00e7a de 95% 1,745\u20138,726, p = 0,001).  Conclus\u00e3o: O presente estudo de mundo real n\u00e3o demonstrou redu\u00e7\u00f5es significativas de hospitaliza\u00e7\u00e3o ou mortalidade com sacubitril\/valsartana em compara\u00e7\u00e3o a enalapril ou losartana nas doses m\u00e1ximas recomendadas pelas diretrizes; no entanto, sacubitril\/valsartana foi associado \u00e0 melhora da classe funcional.<\/jats:p>","DOI":"10.36660\/abc.20260069","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:13:51Z","timestamp":1786540431000},"source":"Crossref","is-referenced-by-count":2,"title":["Sacubitril\/Valsartana versus Enalapril ou Losartana em Doses M\u00e1ximas na Insufici\u00eancia Card\u00edaca com Fra\u00e7\u00e3o de Eje\u00e7\u00e3o Reduzida: Dados de Mundo Real"],"prefix":"10.36660","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7950-1443","authenticated-orcid":false,"given":"Renato de Carvalho","family":"Barros","sequence":"first","affiliation":[{"name":"Universidade de Bras\u00edlia,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0122-7692","authenticated-orcid":false,"given":"Vin\u00edcius C.","family":"Fiusa","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Dados para Qualidade do Cuidado e Pesquisa de Desfechos,  Brasil; Escola Superior de Ci\u00eancias da Sa\u00fade,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5641-8581","authenticated-orcid":false,"given":"Gabrielle N.","family":"Tim","sequence":"additional","affiliation":[{"name":"Escola Superior de Ci\u00eancias da Sa\u00fade,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7965-1128","authenticated-orcid":false,"given":"Victoria T. V.","family":"Goulart","sequence":"additional","affiliation":[{"name":"Escola Superior de Ci\u00eancias da Sa\u00fade,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2518-9597","authenticated-orcid":false,"given":"Caio Henrique M.","family":"Nascimento","sequence":"additional","affiliation":[{"name":"Escola Superior de Ci\u00eancias da Sa\u00fade,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1458-0099","authenticated-orcid":false,"given":"Gustavo T. de","family":"Moura","sequence":"additional","affiliation":[{"name":"Escola Superior de Ci\u00eancias da Sa\u00fade,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2784-820X","authenticated-orcid":false,"given":"Adriana J. B. A.","family":"Guimar\u00e3es","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Dados para Qualidade do Cuidado e Pesquisa de Desfechos,  Brasil; Escola Superior de Ci\u00eancias da Sa\u00fade,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8444-2655","authenticated-orcid":false,"given":"Sergio Henrique Rodolpho","family":"Ramalho","sequence":"additional","affiliation":[{"name":"Instituto S\u00edrio-liban\u00eas de Ensino e Pesquisa,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5592-816X","authenticated-orcid":false,"given":"Armindo","family":"Jreige Jr.","sequence":"additional","affiliation":[{"name":"Instituto de Cardiologia do Distrito Federal,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8017-1675","authenticated-orcid":false,"given":"Filipe A.","family":"Moura","sequence":"additional","affiliation":[{"name":"Yale School of Medicine,  EUA; VA Connecticut Healthcare System,  EUA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6465-356X","authenticated-orcid":false,"given":"Luiz S\u00e9rgio Fernandes de","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Universidade Cat\u00f3lica de Bras\u00edlia,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22636","published-online":{"date-parts":[[2026]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1146\/annurev-med-052915-015509","article-title":"Neprilysin Inhibitors: Emerging Therapy for Heart Failure","volume":"68","author":"Owens AT","year":"2017","journal-title":"Annu Rev Med"},{"issue":"18","key":"ref2","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich PA","year":"2022","journal-title":"Circulation"},{"issue":"36","key":"ref3","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"42","author":"McDonagh TA","year":"2021","journal-title":"Eur Heart J"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure","volume":"371","author":"McMurray JJ","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"ref5","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure","volume":"380","author":"Velazquez EJ","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-Neprilysin Inhibition in Patients with Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure","volume":"82","author":"Mentz RJ","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cardfail.2023.10.467","article-title":"Efficacy and Safety of Sacubitril\/Valsartan in Patients Hospitalized with Heart Failure: A Prespecified, Pooled Individual Patient-Level Analysis of PIONEER-HF and PARAGLIDE-HF","volume":"30","author":"Morrow DA","year":"2024","journal-title":"J Card Fail"},{"key":"ref8","series-title":"Censo Demogr\u00e1fico 2022: Popula\u00e7\u00e3o e Domic\u00edlios: Primeiros Resultados","year":"2023"},{"issue":"1","key":"ref9","first-page":"41","article-title":"Spatial Distribution of Mortality for Heart Failure in Brazil, 1996 - 2017","volume":"118","author":"Cestari VRF","year":"2022","journal-title":"Arq Bras Cardiol"},{"issue":"26","key":"ref10","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJM197112232852601","article-title":"The Natural History of Congestive Heart Failure: The Framingham Study","volume":"285","author":"McKee PA","year":"1971","journal-title":"N Engl J Med"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/jamacardio.2021.4567","article-title":"Effect of Treatment with Sacubitril\/Valsartan in Patients with Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial","volume":"7","author":"Mann DL","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"20","key":"ref12","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction","volume":"385","author":"Pfeffer MA","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"ref13","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00228-024-03686-6","article-title":"Sacubitril\/Valsartan Compared to Equivalent\/Sub-Equivalent Dose Angiotensin Receptor Blocker or Angiotensin-Converting Enzyme Inhibitor in Heart Failure with Reduced Ejection Fraction: A meta-Analysis of Randomized Trials","volume":"80","author":"Rindone JP","year":"2024","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Arquivos Brasileiros de Cardiologia"],"original-title":["Sacubitril\/Valsartan versus Enalapril or Losartan at Maximum Doses in Heart Failure with Reduced Ejection Fraction: Real-World Data"],"link":[{"URL":"https:\/\/abccardiol.org\/wp-content\/uploads\/articles_xml\/0066-782x-abc-123-7-e20260069\/0066-782x-abc-123-7-e20260069.x98474.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:13:54Z","timestamp":1786540434000},"score":1,"resource":{"primary":{"URL":"https:\/\/abccardiol.org\/article\/sacubitril-valsartana-versus-enalapril-ou-losartana-em-doses-maximas-na-insuficiencia-cardiaca-com-fracao-de-ejecao-reduzida-dados-de-mundo-real\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":13,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026]]}},"alternative-id":["S0066-782X2026000700602"],"URL":"https:\/\/doi.org\/10.36660\/abc.20260069","relation":{"is-translation-of":[{"id-type":"doi","id":"10.36660\/abc.20260069i","asserted-by":"subject"},{"id-type":"doi","id":"10.36660\/abc.20260069i","asserted-by":"object"}]},"ISSN":["1678-4170","0066-782X"],"issn-type":[{"value":"1678-4170","type":"electronic"},{"value":"0066-782X","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"e20260069"}}